| ID IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 20% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.84 [0.66 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18952 (Eggermont), | | death (overall survival) | 0.88 [0.74 1.04] | p=1.00 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, | | progression or death (progression free survival PFS) | 0.80 [0.69 0.94] | p=0.04 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| PEG IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.93 [0.81 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | death (overall survival) | 0.96 [0.83 1.12] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | progression or death (progression free survival PFS) | 0.87 [0.76 1.00] | p=0.04 | 0 | -18 | 1 | EORTC18991 (Eggermont), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rIFN alpha-2b vs observation | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | no data | | death (overall survival) | 0.96 [0.76 1.21] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), | | progression or death (progression free survival PFS) | 1.04 [0.84 1.29] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Adjuvant setting: 4 trials - EORTC18871/DKG 80-1 (Kleeberg) - EORTC18952 (Eggermont) - EORTC18991 (Eggermont) - Nordic IFN Trial
| ID IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 20% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.84 [0.66 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18952 (Eggermont), | | death (overall survival) | 0.88 [0.74 1.04] | p=1.00 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, | | progression or death (progression free survival PFS) | 0.80 [0.69 0.94] | p=0.04 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| PEG IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.93 [0.81 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | death (overall survival) | 0.96 [0.83 1.12] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | progression or death (progression free survival PFS) | 0.87 [0.76 1.00] | p=0.04 | 0 | -18 | 1 | EORTC18991 (Eggermont), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rIFN alpha-2b vs observation | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | no data | | death (overall survival) | 0.96 [0.76 1.21] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), | | progression or death (progression free survival PFS) | 1.04 [0.84 1.29] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Adjuvant stage III only - NOVARTIS : 2 trials - EORTC18991 (Eggermont) - EORTC18871/DKG 80-1 stage III
| PEG IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.93 [0.81 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | death (overall survival) | 0.96 [0.83 1.12] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | progression or death (progression free survival PFS) | 0.87 [0.76 1.00] | p=0.04 | 0 | -18 | 1 | EORTC18991 (Eggermont), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rIFN alpha-2b vs observation | No demonstrated result suggested death (overall survival) by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | no data | | death (overall survival) | 1.61 [1.01 2.56] | p=0.04 | 0 | -18 | 1 | EORTC18871/DKG 80-1 stage III, | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 4 trials - EORTC18871/DKG 80-1 (Kleeberg) - EORTC18952 (Eggermont) - EORTC18991 (Eggermont) - Nordic IFN Trial
| ID IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 20% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.84 [0.66 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18952 (Eggermont), | | death (overall survival) | 0.88 [0.74 1.04] | p=1.00 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, | | progression or death (progression free survival PFS) | 0.80 [0.69 0.94] | p=0.04 | 0 | -36 | 2 | EORTC18952 (Eggermont),Nordic IFN Trial, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| PEG IFN alpha-2b (I M) vs observation | No demonstrated result suggested progression or death (progression free survival PFS) by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | 0.93 [0.81 1.07] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | death (overall survival) | 0.96 [0.83 1.12] | p=1.00 | 0 | -18 | 1 | EORTC18991 (Eggermont), | | progression or death (progression free survival PFS) | 0.87 [0.76 1.00] | p=0.04 | 0 | -18 | 1 | EORTC18991 (Eggermont), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rIFN alpha-2b vs observation | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| distant metastasis free survival | no data | | death (overall survival) | 0.96 [0.76 1.21] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), | | progression or death (progression free survival PFS) | 1.04 [0.84 1.29] | p=1.00 | 0 | -18 | 1 | EORTC18871/DKG 80-1 (Kleeberg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
